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introduction
One of the characteristic hallmarks of alzheimer’s disease
(ad) is a progressive deterioration in the ability to perform
activities of daily living (adl), as well as impairments in
cognition, visuospatial function and memory (1). One of the
primary causes of ad symptomatology is believed to be
synaptic loss, particularly in the hippocampal and cortical
synapses (2, 3). 
Preclinical research has suggested that the ingestion of
certain nutrients may help to improve the formation of new
synapses in the brain. specifically, these include the rate-
limiting precursors uridine, choline, and docosahexaenoic acid
(dHa), involved in the synthesis of the synaptic membrane
phosphatides essential for neuronal formation and function 
(4-6). B-vitamins, phospholipids and antioxidants also serve as
co-factors by enhancing the availability of these precursors (7).
combined dietary enrichment with these nutrients has also been
shown to influence membrane-dependent processes, e.g.
reducing amyloid precursor processing pathways and receptor
function. this, in turn, could result in reduced amyloid-beta
production, plaque burden and amyloid-beta toxicity (8). in
support of this, epidemiological and cohort studies suggest that
a diet rich in omega-3 fatty acids, B-vitamins, and antioxidants
decreases the risk of ad (9, 10), while other studies suggest
that patients with ad have lower plasma levels of these
nutrients when compared with cognitively intact age-matched
controls (11).
these observations led to the development of souvenaid®, a
multi-nutrient drink designed to deliver the supporting nutrients
to improve synaptic membrane formation and function in
patients with ad. this medical food contains a specific
formulation of nutrients registered as Fortasyn™ connect
(including dHa, eicosapentanoic acid, phospholipids, choline,
uridine monophosphate, vitamins B12, B6, and folate, vitamins
c and e and selenium), along with other vitamins, minerals,
trace elements and macronutrients (12). the efficacy and
tolerability of souvenaid in mild ad was investigated in a 24-
week, multicenter, controlled, proof-of-concept study (12).
memory performance was significantly improved in the group
that received souvenaid versus the control group (12).
in the early course of ad, the more complex instrumental
adl such as shopping, preparing a meal and handling finances
have already begun to deteriorate (13). at the same time, ad
patients face a risk of malnutrition and weight loss that is
thought to influence the evolution and worsening of the
condition and predict mortality (14-16). Poor nutritional status
has also been shown to be closely related to the occurrence of
functional deficits, even at the initial stages of ad (17, 18).
Body mass index (Bmi) is a widely accepted indicator of
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nutritional status (19), and was used in the current study.
the relationship between Bmi and functional abilities
formed the rationale for the analyses presented here. these
investigated whether baseline Bmi impacts the effect of
souvenaid on functional abilities in patients with mild ad. in
addition, the influence of the medical food on Bmi was
assessed.
methods
Study design
the proof-of-concept study with souvenaid was a 12-week,
double-blind, randomized, controlled, multicenter study with a
similarly designed, exploratory, optional 12-week extension
period. the detailed methodology and primary results of the
study have been described previously (12). Briefly, 225 patients
with mild ad (mini-mental state examination [mmse] score
of 20–26) were recruited and randomized 1:1 to receive either
the active (souvenaid®, Nutricia N.V., Zoetermeer, the
Netherlands) or iso-caloric control product as a 125 ml drink to
be taken every day (12). in line with current guidelines for
clinical trials in ad (20), the study included measures of
cognition (modified alzheimer's disease assessment scale-
cognitive subscale, primary outcome) (21) and functional
abilities (23-item alzheimer’s disease cooperative study-adl
[adcs-adl], secondary outcome) (22). the adcs-adl
scale is rated by the caregiver and ranges from 0 (need for
extensive help) to 78 (independent performance). Baseline
height and weight measurements were used to calculate Bmi
(kg/m2). Both adcs-adl and body weight were assessed at
baseline, Week 6, 12 and 24 (height was measured at baseline
only).
the study was conducted in accordance with the declaration
of Helsinki and the international conference on Harmonisation
of technical Requirements for Registration of Pharmaceuticals
for Human use / WHO Good clinical Practice (icH-GcP)
guidelines, as appropriate to the legislation of the countries
participating in the study. the clinical trial registration number
is isRctN72254645.
Modeling analysis
the primary analysis population was the intent-to-treat (itt)
efficacy population, defined as all patients who received at least
one dose of study product and one post-baseline assessment.
the per-protocol (PP) efficacy population consisted of all
patients who completed the study without major protocol
deviations. Patients who did not receive any study product for 
> 25% of days, and/or patients who received < 70% of the
prescribed dosage overall, were excluded from the PP group.
data were analyzed with a linear repeated-measures mixed
(Rmm) model, using sas® software version 9.2. the current
data showed the best fit with the Rmm model and
Heterogeneous compound symmetry variance–covariance
structure where time was treated as a categorical variable and
represented by dummy codes. exploratory additional
comparisons were performed using contrast statements.
Prior to the modeling analyses, the adcs-adl data were
transformed using a quadratic transformation to adjust for the
skewed nature of the data. similarly, a square-root
transformation was applied to Bmi data.
results
in the initial proof-of-concept study, 225 patients were
randomized to treatment, of whom 112 received active product
and 113 received control product. Overall, 161 patients
completed the 24-week study (12). Of the 212 patients in the
itt efficacy population (12), 144 were included in the PP
analysis population. No statistically significant differences
between active or control groups were reported for any baseline
characteristic (table 1).
table 1
Baseline characteristics for the itt population (12)
characteristics control product active product
total patient population (n = 106) (n = 106)
men, n (%) 52 (49) 54 (51)
age (yr)
mean ± sd 73.3 ± 7.8 74.1 ± 7.2
mmse 
mean ± sd 24.0 ± 2.5 23.8 ± 2.7
total adcs-adl 
mean ± sd 61.9 ± 10.9 61.1 ± 10.5
median [range] 64.5 [10 – 77] 63.0 [28 – 78]
Bmi 
mean ± sd 26.2 ± 3.5 26.2 ± 4.8
median [range] 26.0 [18 – 37] 25.5 [15 – 41]
‘low’ baseline BMi group (n = 52) (n = 60)
men, n (%) 28 (54) 31 (52)
age (yr)
mean ± sd 72.2 ± 8.4 74.9 ± 7.0
mmse 
mean ± sd 24.4 ± 2.4 23.9 ± 2.5
total adcs-adl 
mean ± sd 62.3 ± 11.5 60.7 ± 10.4
median [range] 65.0 [10 – 77] 63.0 [28 – 78]
Bmi 
mean ± sd 23.4 ± 1.7 23.2 ± 2.6
median [range] 23.8 [18 – 26] 23.6 [15 – 27]
‘high’ baseline BMi group (n = 51) (n = 40)
men, n (%) 23 (45) 20 (50)
age (yr)
mean ± sd 74.3 ± 7.1 73.0 ± 7.5
mmse
mean ± sd 23.5 ± 2.6 23.6 ± 2.5
total adcs-adl 
mean ± sd 61.9 ± 10.5 61.8 ± 11.2
median [range] 62.0 [36 – 77] 63.0 [29 – 78]
Bmi
mean ± sd 29.0 ± 2.4 30.8 ± 3.5
median [range] 28.4 [26 – 37] 30.1 [26 – 41]
adcs-adl = alzheimer’s disease cooperative study-activities of daily living (0–78;
higher scores indicate greater functioning); Bmi = Body mass index; mmse = mini-
mental state examination (0–30; lower scores indicate greater cognitive dysfunction).
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Treatment effect on BMI
in the entire study population, data suggested an increased
Bmi in the active study group versus the control group at Week
24 (itt: p = 0.07; PP: p = 0.03), but not at Week 12 (itt: 
p = 0.39; PP: p = 0.42; Figure 1, table 2). 
table 2
estimated marginal mean (95% confidence interval) Bmi
values over 24 weeks for patients receiving active or control
product
Estimated marginal mean bmi in entire study population 
(itt)
n* control n active
Baseline 103 26.1 (25.3 – 26.9) 100 26.0 (25.2 – 26.8)
Week 6 97 26.2 (25.4 – 27.0) 96 26.2 (25.4 – 27.0)
Week 12 97 26.2 (25.4 – 27.0) 98 26.3 (25.5 – 27.1) 
Week 24 76 26.2 (25.4 – 27.0) 76 26.4 (25.6 – 27.2)
*Not all patients provided Bmi data at all timepoints; Bmi = Body mass index; itt =
intention to treat. data are back transformed; transformed [square-root] data were squared.
12-week, active versus control: itt: p = 0.39; PP: p = 0.42. 24-week active versus control:
itt: p = 0.07; PP: p = 0.03.
figure 1
estimated marginal mean Bmi change from baseline over 24
weeks. itt; back-transformed data
Treatment effect on ADL
Overall, no treatment effect on adcs-adl was observed.
However, baseline Bmi was found to be a significant treatment
effect modifier (itt: p = 0.04; PP: p = 0.05) indicating that
Bmi significantly affected the adcs-adl response of
souvenaid. in order to study whether this effect was
predominantly driven by low or high Bmi, patients were
divided into two subgroups: those with a baseline Bmi less
than or equal to the mean (26.2 kg/m2) and those above the
mean. 
ADL effect in the subgroups of patients with ‘high’ or
‘low’ baseline BMI
No intervention effect on adl outcome was observed in the
subgroup of patients with ‘high’ baseline Bmi (Week 12, itt:
p = 0.23; PP: p = 0.18, Week 24, itt: p = 0.17; PP: p = 0.17).
Within the ‘low’ baseline Bmi subgroup, the Rmm model
indicated an increase of adcs-adl scores at Week 12 in the
active study group versus the control group (itt: p = 0.02; PP:
p = 0.04). However, no significant difference was observed at
Week 24 (itt: p = 0.20; PP: p = 0.10; Figure 2, table 3).
table 3
estimated marginal mean (95% confidence interval) adcs-
adl scores over 24 weeks for patients receiving active or
control product with a ‘low’ (≤ mean) baseline Bmi
Estimated marginal mean adcs-adl in ‘low’ bmi subgroup 
(itt)
n control n active
Baseline 52 63.5 (60.6 – 66.2) 60 61.7 (58.8 – 62.4)
Week 6 50 64.5 (61.6 – 67.2) 57 63.4 (60.7 – 66.1)
Week 12 49 62.7 (59.7 – 65.6) 56 63.9 (61.1 – 66.6)
Week 24 37 62.5 (59.1 – 65.7) 45 62.6 (59.4 – 65.6)
adcs-adl = alzheimer’s disease cooperative study-activities of daily living (0–78;
higher scores indicate greater functioning); Bmi = Body mass index; itt = intention to
treat. 12-week active versus control: itt: p = 0.02; PP: p = 0.04; 24-week active versus
control: itt: p = 0.20; PP: p = 0.10. data are back transformed; transformed [squared]
data underwent a square-root calculation.
figure 2
estimated marginal mean adcs-adl change from baseline
over 24 weeks in the subgroup of patients with ‘low’ (≤ mean)
baseline Bmi. itt; back-transformed data
exploratory analyses using contrast statements were
conducted to further investigate the effect of treatment on adl
response in patients with ‘low’ baseline Bmi. When baseline
adcs-adl was contrasted against all post-baseline
assessments, no significant treatment effect was observed (itt:
p = 0.08, PP: p = 0.13). there was an apparent placebo effect
observed at Week 6 on the adcs-adl (illustrated in Figure
2). to adjust for this, the baseline and Week 6 adcs-adl
scores were combined and contrasted against the Week 12 and
Week 24 adcs-adl scores (combined). this exploratory
analysis showed a significant treatment effect (itt: p = 0.03,
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PP: p = 0.01) suggesting that the effect of souvenaid versus
control on adl performance within the ‘low’ Bmi subgroup
may only be observable after at least 6 weeks of treatment.
sensitivity analyses showed that the results were
independent of transformation used and type of covariance
structure chosen.
discussion
in addition to the effects of souvenaid on memory
performance described previously (12), this report presents the
positive effect of the multi-nutrient product on Bmi. in
addition, the modeling analyses presented here indicated that
baseline Bmi significantly influenced the effect of souvenaid
on adcs-adl performance, and that souvenaid improved
adcs-adl in a subgroup of mild ad patients with ‘low’
baseline Bmi.
this is the first study to suggest that increased Bmi can be
achieved with a specific combination of nutrients, independent
of the energy content of the product, in patients with mild ad.
the influence of omega-3 fatty acids on body weight and Bmi
in patients with mild to moderate ad has been previously
reported (23). However, weight loss is more likely to occur in
patients with mild to moderate ad versus a mild ad
population (14). a study conducted by Faxén-irving et al. (23)
showed that an increase in body weight correlated with an
increase in Neuropsychiatric inventory (NPi) appetite score,
although food intake data were not collected (23). 
there was insufficient variance in the NPi appetite scores in
the current study to investigate the correlation with Bmi. Food
intake was not measured and so the extent to which this factor
may have contributed to the improved Bmi is not known.
unpublished preclinical studies of iso-caloric diets with and
without the specific nutrient mixture Fortasyntm connect have
shown that body weight increases as a result of this nutrient
combination. these results suggest that the observed increase in
Bmi may be independent of energy intake. the mechanism by
which Fortasyntm connect contributes to improved Bmi
warrants clarification in future research. at present we can only
speculate: it may be that changes in the basal metabolic rate or
activation of biochemical pathways contribute to an increase in
Bmi. alternatively, improved lifestyle and eating habits may
also have resulted in increased Bmi. methods to investigate
these hypotheses should be incorporated into future clinical
studies.
adcs-adl performance was significantly improved in a
subgroup of patients with ‘low’ baseline Bmi. additional
analyses showed that the treatment effect appeared to be
primarily driven by an improvement in instrumental adl
rather than basic adl (data not shown). deficits in
instrumental adl are known to occur in the early stage of ad
(13) and have been associated with disease progression (24). 
Previous research has demonstrated that among community-
dwelling patients with ad, those with a lower Bmi and
nutritional status exhibit a faster decline in functional capability
(25, 26). the impact of souvenaid on adl performance in the
‘low’ Bmi subgroup may therefore be due to the faster natural
decline in this subgroup presenting a greater opportunity for
improvements in functional performance. Furthermore,
decreased activity, reduced metabolic cell mass, and lower
energy expenditure in the elderly result in reduced dietary
intake and a lower intake of nutrients (27). this may also help
to explain the functional treatment effect bestowed by the
nutrient formulation (Fortasyntm connect) in souvenaid.
However, it should be noted that the statistical phenomenon of
linear regression to the mean could also have contributed to the
apparent treatment effect. this effect should therefore be
regarded as an exploratory finding.
the mean Bmi for the ‘low’ baseline Bmi subgroup was
23.3 kg/m2, which can be regarded as suboptimal, as previous
research has shown a Bmi < 23 kg/m2 to be associated with
poorer 7-year survival in patients with ad (23, 28). in addition,
a Bmi of ≤ 23.5 kg/m2 has been defined as one of the
contributing factors to frailty in elderly people (29). However,
Bmi itself should not be considered a complete measure of
nutritional status, and the follow-up studies with souvenaid will
include other parameters to obtain a more comprehensive
overview of the patient’s nutritional status.
the results presented here suggest that baseline Bmi is a
predictor of adl outcome. the data indicated that patients
with lower Bmi at baseline may benefit more from souvenaid,
with respect to functional outcome, than those with higher
baseline Bmi. in addition, there was a suggestion that
souvenaid improved Bmi in the entire study population. the
current observations may be important for clinical care. 
these findings warrant confirmation in larger, more highly
powered, controlled clinical studies in which subgroups of
patients with worsening nutritional status receive further
attention. these studies will include measures to confirm and
extend the observed Bmi-dependent effects of souvenaid on
adl performance and will provide more data on the nutritional
status of the patients. 
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